RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study

• Published in: Annals of oncology Vol. 29; no. 5; pp. 1211 - 1219
• Main Authors: Bachet, J.B., Bouché, O., Taieb, J., Dubreuil, O., Garcia, M.L., Meurisse, A., Normand, C., Gornet, J.M., Artru, P., Louafi, S., Bonnetain, F., Thirot-Bidault, A., Baumgaertner, I., Coriat, R., Tougeron, D., Lecomte, T., Mary, F., Aparicio, T., Marthey, L., Taly, V., Blons, H., Vernerey, D., Laurent-Puig, P.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.05.2018; Oxford University Press; Elsevier
• Subjects: accuracy; Adult; Aged; Aged, 80 and over; Biochemistry, Molecular Biology; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Cancer; circulating tumor DNA; Circulating Tumor DNA - genetics; colorectal cancer; Colorectal Neoplasms - blood; Colorectal Neoplasms - genetics; Colorectal Neoplasms - pathology; DNA Mutational Analysis - methods; Female; Humans; Life Sciences; liver metastases; Liver Neoplasms - blood; Liver Neoplasms - genetics; Liver Neoplasms - secondary; Male; methylated biomarker; Middle Aged; NGS; Patient Selection; Predictive Value of Tests; Prospective Studies; Randomized Controlled Trials as Topic; ras Proteins - genetics; Young Adult; accuracy; colorectal cancer; methylated biomarker; NGS; liver metastases; circulating tumor DNA

RAS mutations are currently sought for in tumor samples, which takes a median of almost 3weeks in western European countries. This creates problems in clinical situations that require urgent treatment and for inclusion in therapeutic trials that need RAS status for randomization. Analysis of circula...